XM does not provide services to residents of the United States of America.
W
W

Waters

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. Humana, Portillos, Waters Corp

U.S. RESEARCH ROUNDUP-Humana, Portillos, Waters Corp Oct 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Humana, Portillos and Waters on Tuesday. HIGHLIGHTS * Frontier Communications Parent Inc FYBR.O : TD Cowen cuts to hold from buy * Humana HUM.N : RBC cuts target price to $265 from $400 * Portillos Inc PTLO.O : Stephens cuts to equal-weight from overweight * Waters Corp WAT.N : Jefferies raises to buy from hold
B
C
C
C
H
C
F
G
S
W
C
C
P

U.S. STOCKS Gold miners, silver miners, Warner Bros Discovery

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was little changed on Thursday after hot producer prices data kept a smaller, 25-basis-point interest-rate cut by the Federal Reserve firmly on the table, while vaccine maker Moderna's shares slumped following a downbeat revenue forecast.
G
K
M
U
U
D
W
A

Waters Corp Appoints Heather Knight To Board Of Directors

BRIEF-Waters Corp Appoints Heather Knight To Board Of Directors Aug 14 (Reuters) - Waters Corp WAT.N : WATERS CORPORATION APPOINTS HEATHER KNIGHT TO BOARD OF DIRECTORS Source text for Eikon: ID:nPnc7ZkDqa Further company coverage: WAT.N
W

Mettler-Toledo forecast dull third-quarter profit on weak China demand

Mettler-Toledo forecast dull third-quarter profit on weak China demand Aug 1 (Reuters) - Medical equipment maker Mettler-Toledo International MTD.N forecast third-quarter profit below estimates on Thursday, a sign of a weaker-than-expected recovery in sales in its key market China. Lifesciences firms including lab equipment maker Mettler-Toledo have seen sluggish demand for their instruments used in drug development as cash-strapped biotech clients try to navigate a funding crunch amid high inte
W
M

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products Aug 1 (Reuters) - Bio-Rad Laboratories BIO.N cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients. Shares of the diagnostics company fell 20% after the bell. Bio-Rad expects its full-year 2024 adjusted revenue to decline by about 2.5% to 4% on a currency-neutral basis, compared to its previous estimate of 1.0% to 2.5%.
T
W

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.